Moolec Science SA (MLEC) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals financial strain with increased expenses and limited cash position, despite some revenue growth. Market competition poses challenges, and the Q&A highlights uncertainties in customer commitments and regulatory timelines. Although there are positive developments like USDA approval, the overall sentiment is cautious, with financial and operational risks overshadowing potential gains.
Key Financial Performance
Normalized Revenues and Other Income Approximately $1.3 million, increased from nil year-over-year due to the consolidation of the soy protein ingredient business in April 2023.
Normalized Costs of Goods Sold Close to $1 million, increased from nil year-over-year, resulting in a gross margin of around 18%.
SG&A and R&D Expenses $2.3 million, increased from $1.4 million in Q3 2023, mainly due to non-cash items such as depreciation, amortization, equity incentives, and the consolidation of the soy ingredient business.
Operational Cash Flow Approximately $2.7 million, decreased from $4.2 million in Q3 2023, due to significantly lower cash payments associated with listing costs.
Cash Position Approximately $4.3 million as of Q3 2024, strengthened by approximately $2 million of additional funding received in April 2024 from the equity line of credit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Piggy Sooy: Moolec achieved regulatory approval from USDA-APHIS for Piggy Sooy, allowing the company to ship products without individual permits. This platform technology enables high expression of animal meat proteins in soybeans.
GLASO: Moolec's gamma-linolenic acid safflower oil (GLASO) is in pre-commercialization stages, with trial production of 5 tons initiated and 600 acres contracted for production.
SPC2: Two U.S. patents granted for SPC2, extending protection of technology and processes until 2041.
Market Potential of Piggy Sooy: Piggy Sooy targets the $700 billion market of processed meat products, aiming to replace traditional soy protein ingredients with a more nutritious alternative.
Operational Cash Flow: Operational cash flow for Q3 2024 was approximately $2.7 million, a decrease from $4.2 million in Q3 2023.
Cash Position: Cash position as of Q3 2024 was approximately $4.3 million, bolstered by $2 million in funding from an equity line of credit.
Commercialization Timeline: Commercialization of Piggy Sooy is expected to begin in 2027-2028, following field trials and breeding strategies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces inherent risks and uncertainties related to forward-looking statements, particularly in the context of regulatory approvals and compliance with USDA-APHIS regulations.
Supply Chain Challenges: Moolec's commercialization process for Piggy Sooy is projected to begin in 2027-2028, which may face supply chain challenges during the scaling up of production.
Competitive Pressures: The company operates in a highly competitive market, particularly in the $700 billion global meat market, where traditional soy protein ingredients are prevalent.
Financial Risks: Increased SG&A and R&D expenses from $1.4 million to $2.3 million in Q3 2024 may impact financial stability, especially with operational cash flow decreasing from $4.2 million to $2.7 million year-over-year.
Market Adoption Risks: The success of Moolec's products, such as Piggy Sooy and GLASO, depends on market acceptance and the ability to replace traditional meat products, which may pose adoption risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Approval of Piggy Sooy: Moolec achieved regulatory approval from USDA-APHIS for Piggy Sooy, allowing the company to move and ship products without individual permits.
Commercialization Timeline: Commercialization of Piggy Sooy is expected to begin in 2027-2028, following field trials and breeding strategies.
Safflower Platform Development: GLASO is in pre-commercialization stages with trial production started and contracts for 600 acres of production secured.
Intellectual Property Expansion: Two U.S. patents granted for SPC2, extending protection until 2041, as part of Moolec's strategy to build its IP portfolio.
Revenue Expectations: Normalized revenues increased to approximately $1.3 million in Q3 2024, attributed to the consolidation of the soy protein ingredient business.
Gross Margin: Gross margin for Q3 2024 was around 18%.
Cash Position: Cash position as of Q3 2024 was approximately $4.3 million, bolstered by $2 million in additional funding.
Operational Cash Flow: Operational cash flow for Q3 2024 was approximately $2.7 million, a decrease from $4.2 million in Q3 2023.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: Approximately $4.3 million as of Q3 2024, strengthened by approximately $2 million of additional funding received during the end of April 2024.
Operational Cash Flow: Operational cash flow this quarter was approximately $2.7 million.
SG&A and R&D Expenses: Increased to $2.3 million from $1.4 million in Q3 2023.
Normalized Revenues: Increased year-over-year from nil to approximately $1.3 million.
Gross Margin: Around 18%.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more color on the significance of USDA approval for Piggy Sooy, what's next and the opportunity you see?
A:We are really happy to be the first molecular farming company to achieve USDA approval. This approval indicates no patch risk in implanting our animal proteins in U.S. soil. We are currently planting Piggy Sooy in three locations in the U.S. without permits, and we have started conversations with the FDA.
Q:Can you talk more about the types of customers and timing of commercialization for GLASO?
A:GLASO is in pre-commercialization stages targeting pet foods, dietary supplements, and nutritional beverages. We are planting around 600 acres in Idaho and hope to hit the market by early 2025.
Q:When can you expect commitments from customers for Piggy Sooy? Have you had feedback from potential customers?
A:It's hard to say specific timing for customer commitments, but we are receiving good feedback and have started delivering samples. We are currently increasing seed production.
Q:Can you provide more color on the conversations you're having with ingredient foods and dietary supplements?
A:I can't reveal names of potential customers, but we are working to close off-take agreements and commercial agreements. Interest is coming from multiple industries, but we are prioritizing food applications.
Q:Can you provide an update on the YEA1 scale-up process and timing for regulatory compliance?
A:YEA1 is on track, and we are scaling up with our partner in Europe. This will provide samples and information for regulators. The yeast product may progress faster than plant products due to controlled environments.
Q:How has your outlook on the hyperinflationary environment in Argentina changed recently?
A:Argentina's inflation is going down, and we have some exposure to inflation in our cost structure. Our revenues are mostly in U.S. dollars, so inflation shouldn't have a large impact. We expect a gradual devaluation of the Argentine peso and a strong decline in inflation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific names of potential customers for GLASO and Piggy Sooy, which lacked clarity on the exact nature of the conversations. Additionally, the response regarding the timing of customer commitments for Piggy Sooy was vague, indicating good feedback but no specific commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Argentina
CO emission
Europe
GLASO
Group Fortune
President
USDA APHIS
USDA approval
YEA
achievement
acre
basis
beginning
conversation
devaluation
environment
feedback
food application
footprint
front
inflation rate
information regulator
ingredient food
livestock
meat product
meat protein
name firm
omega
patent
peso
pig
planet
protein ingredient
safflower platform
sample
step
supplement
timing
trial
utilization
water
way
MLEC Transcript
Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Unknown10-2
The earnings call presents a mixed picture. While there are positive developments like the collaboration with a major CPG company and Bunge, and revenue growth, there are significant concerns. Financial risks are evident with increased cash utilization and reliance on convertible notes. Operational risks and competitive pressures also loom large. The Q&A section highlighted some positive partnerships but lacked clarity on revenue specifics, adding uncertainty. Overall, these factors balance each other, leading to a neutral sentiment with potential for minor fluctuations in stock price.
Moolec Science SA (MLEC) Q3 2024 Earnings Call Transcript
Unknown5-30
The earnings call reveals financial strain with increased expenses and limited cash position, despite some revenue growth. Market competition poses challenges, and the Q&A highlights uncertainties in customer commitments and regulatory timelines. Although there are positive developments like USDA approval, the overall sentiment is cautious, with financial and operational risks overshadowing potential gains.
Moolec Science SA (MLEC) Q1 2024 Earnings Call Transcript
Positive12-14
The earnings call reveals a 92% revenue increase, reduced admin expenses, and strong operational cash utilization. Positive developments in R&D, such as high yield and protein expression levels, bolster sentiment. While there are risks like Argentina's economic reforms, the company's limited exposure minimizes impact. The Q&A highlights strategic lab setup, focus on cash flow, and successful field trials, adding to optimism. Overall, the positive financial performance and strategic advancements suggest a likely stock price increase in the coming weeks.
Moolec Science SA (MLEC) Q3 2023 Earnings Call Transcript
Neutral5-31
MLEC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
